Prognosis of sarcoidosis and factors affecting prognosis

Main Article Content

Bilge Bilgin https://orcid.org/0000-0001-6035-9195
Mehmet Kursat Bilgin https://orcid.org/0000-0002-9366-5313
Serhat Erol https://orcid.org/0000-0003-1645-7761
Gokhan Celik https://orcid.org/0000-0003-0869-8979
Ozlem Ozdemir Kumbasar https://orcid.org/0000-0003-4599-1461

Keywords

Fibrosis, Mortality, Prognosis, Pulmonary Hypertension, Sarcoidosis

Abstract

Introduction: Sarcoidosis is a multi-system disease of unknown etiology characterized by non-caseating granulomatous inflammation. Determining the characteristics and prognosis of sarcoidosis cases and revealing the factors that may affect the prognosis are important for approach to patient. This study was planned to obtain prognosis data for our country and to determine the factors affecting the prognosis. Patients and methods: 188 patients, followed regularly for three years or more, admitted to Ankara University Faculty of Medicine, Department of Chest Diseases between 2012-2017 were evaluated retrospectively. Increased radiological findings, functional impairment and any of the clinical conditions requiring initiation/modification of treatment were accepted as progression. Clinical status of the patients at the last follow-up was defined as remission with treatment, spontaneous remission, stable disease, progression, chronic case and recurrence. Spontaneous remission and remission with treatment, regression, stable disease, and recurrence that followed without treatment and didn’t cause symptom or functional impairment were accepted in good prognosis group. Progression, chronic cases that couldn’t be followed without treatment and recurrence requiring treatment were included in poor prognosis group. Results: 58% of patients was accepted in good prognosis and 42% had poor prognosis group. During follow-up, spontaneous remission rate was 20.2%, pulmonary hypertension development rate was 10.6% and mortality rate was 4.25%. Low radiological stage, high spirometry and diffusion capacity values, being asymptomatic and having no previous treatment were associated with spontaneous remission and good prognosis. Increase in serum angiotensin converting enzyme and C-reactive protein and decrease in spirometry parameters and diffusion capacity values were associated with progression.

Downloads

Download data is not yet available.
Abstract 340 | PDF Downloads 296

References

1. West SG. Current management of sarcoidosis I: pulmonary, cardiac, and neurologic manifestations. Curr Opin Rheumatol. 2018;30(3):243-8.
2. Sarcoidosis So. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160(2):736-55.
3. Walsh SL, Wells AU, Sverzellati N, et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med. 2014;2(2):123-30.
4. Kirkil G, Lower EE, Baughman RP. Predictors of Mortality in Pulmonary Sarcoidosis. Chest. 2018;153(1):105-13. Epub 2017/07/22. doi: 10.1016/j.chest.2017.07.008. PubMed PMID: 28728933.
5. Baughman RP, Wells A. Advanced sarcoidosis. Curr Opin Pul Med. 2019;25(5):497-504.
6. Culver DA, Judson MA. New advances in the management of pulmonary sarcoidosis. Bmj. 2019;367:l5553.
7. Wells AU. Sarcoidosis: A benign disease or a culture of neglect? Respir Med. 2018;144:S1-S2.
8. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed). 2016;69(2):177. doi: 10.1016/j.rec.2016.01.002. PubMed PMID: 26837729.
9. Prasse A, Katic C, Germann M, Buchwald A, Zissel G, Müller-Quernheim J. Phenotyping sarcoidosis from a pulmonary perspective. Am J Respir Crit Care Med. 2008;177(3):330-6.
10. Musellim B, Kumbasar O, Ongen G, et al. Epidemiological features of Turkish patients with sarcoidosis. Respir Med. 2009;103(6):907-12.
11. Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Muller-Quernheim J. Sarcoidosis. Lancet. 2014;383(9923):1155-67. Epub 2013/10/05. doi: 10.1016/S0140-6736(13)60680-7. PubMed PMID: 24090799.
12. Deubelbeiss U, Gemperli A, Schindler C, Baty F, Brutsche MH. Prevalence of sarcoidosis in Switzerland is associated with environmental factors. Eur Respir J. 2010;35(5):1088-97.
13. Arkema EV, Grunewald J, Kullberg S, Eklund A, Askling J. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J. 2016;48(6):1690-9.
14. Aykan FS, Türktaş H, Köktürk N, Akten SY. Retrospective Evaluation of 100 Patients with Sarcoidosis in Gazi University, Turkey. Turk Thorac J. 2014;15(4).
15. Kiter G, Müsellim B, Cetinkaya E, et al. Clinical presentations and diagnostic work-up in sarcoidosis: a series of Turkish cases (clinics and diagnosis of sarcoidosis). Tuberk Toraks. 2011;59(3):248-58.
16. Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170(12):1324-30.
17. Judson MA, Baughman RP, Thompson BW, et al. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20(3):204-11.
18. Costabel U, Hunninghake GW. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur Respir J. 1999;14(4):735-7. Epub 1999/11/26. doi: 10.1034/j.1399-3003.1999.14d02.x. PubMed PMID: 10573213.
19. Vorselaars AD, Cremers JP, Grutters JC, Drent M. Cytotoxic agents in sarcoidosis: which one should we choose? Curr Opin Pul Med. 2014;20(5):479-87.
20. Costabel U. Sarcoidosis: clinical update. Eur Respir J. 2001;18(32 suppl):56s-68s.
21. Costabel U, Teschler H. Biochemical changes in sarcoidosis. Clin Chest Med. 1997;18(4):827-42.
22. Bargagli E, Prasse A. Sarcoidosis: a review for the internist. Intern Emerg Med. 2018;13(3): 325-31.
23. Grunewald J, Grutters JC, Arkema EV, Saketkoo LA, Moller DR, Muller-Quernheim J. Sarcoidosis. Nat Rev Dis Primers. 2019;5(1):45. Epub 2019/07/06. doi: 10.1038/s41572-019-0096-x. PubMed PMID: 31273209.
24. Kahkouee S, Samadi K, Alai A, Abedini A, Rezaiian L. Serum ACE level in sarcoidosis patients with typical and atypical HRCT manifestation. Pol J Radiol. 2016;81:458.
25. Gungor S, Ozseker F, Yalcinsoy M, et al. Conventional markers in determination of activity of sarcoidosis. Int Immunopharmacol. 2015;25(1):174-9.
26. Soto-Gomez N, Peters JI, Nambiar AM. Diagnosis and Management of Sarcoidosis. Am Fam Physician. 2016;93(10).
27. Vestbo J, Viskum K. Respiratory symptoms at presentation and long-term vital prognosis in patients with pulmonary sarcoidosis. Sarcoidosis. 1994;11(2):123-5.
28. Judson MA, Preston S, Hu K, et al. Quantifying the relationship between symptoms at presentation and the prognosis of sarcoidosis. Respir Med. 2019;152:14-9.
29. Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H. Outcome in sarcoidosis: the relationship of relapse to corticosteroid therapy. Chest. 1997;111(3):623-31.
30. Rossides M, Kullberg S, Askling J, Eklund A, Grunewald J, Arkema EV. Sarcoidosis mortality in Sweden: a population-based cohort study. Eur Respir J. 2018;51(2):1701815.
31. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011;183(5):573-81.
32. Lau EM, Tamura Y, McGoon MD, Sitbon O. The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress. Eur Respir J. 2015.
33. Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest. 2010;138(5):1078-85.
34. Rapti A, Kouranos V, Gialafos E, et al. Elevated pulmonary arterial systolic pressure in patients with sarcoidosis: prevalence and risk factors. Lung. 2013;191(1):61-7.
35. Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest. 2006;129(5):1246-52.
36. Baughman RP, Shlobin OA, Wells AU, et al. Clinical features of sarcoidosis associated pulmonary hypertension: results of a multi-national registry. Respir Med. 2018;139:72-8.
37. Parikh KS, Dahhan T, Nicholl L, et al. Clinical Features and outcomes of patients with sarcoidosis-associated pulmonary Hypertension. Sci Rep. 2019;9(1):4061.
38. Candemir I, Kumbasar OO. Echocardiographic Measurement of Pulmonary Arterial Pressure in Patients with Sarcoidosis. Open J Res Dis. 2016;06(01):7-13. doi: 10.4236/ojrd.2016.61002.
39. Nardi A, Brillet P-Y, Letoumelin P, et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J. 2011;38(6):1368-73.
40. Pena TA, Soubani AO, Samavati L. Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature. Lung. 2011;189(2):167-72.

Most read articles by the same author(s)